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Abstract
Background: Physical stress triggers the endothelium to release von Willebrand Factor (VWF) from the Weibel Palade
bodies. Since VWF is a risk factor for arterial thrombosis, it is of great interest to discover determinants of VWF response to
physical stress. We aimed to determine the main mediators of the VWF increase by exhaustive physical exercise.
Methods: 105 healthy individuals (18–35 years) were included in this study. Each participant performed an incremental
exhaustive exercise test on a cycle ergometer. Respiratory gas exchange measurements were obtained while cardiac
function was continuously monitored. Blood was collected at baseline and directly after exhaustion. VWF antigen (VWF:Ag)
levels, VWF collagen binding (VWF:CB) levels, ADAMTS13 activity and common variations in Syntaxin Binding Protein-5
(STXBP5, rs1039084 and rs9399599), Syntaxin-2 (STX2, rs7978987) and VWF (promoter, rs7965413) were determined.
Results: The median VWF:Ag level at baseline was 0.94 IU/mL [IQR 0.8–1.1] and increased with 47% [IQR 25–73] after
exhaustive exercise to a median maximum VWF:Ag of 1.38 IU/mL [IQR 1.1–1.8] (p,0.0001). VWF:CB levels and ADAMTS13
activity both also increased after exhaustive exercise (median increase 43% and 12%, both p,0.0001). The strongest
determinants of the VWF:Ag level increase are performance related (p,0.0001). We observed a gender difference in VWF:Ag
response to exercise (females 1.2 IU/mL; males 1.7 IU/mL, p = 0.001), which was associated by a difference in performance.
Genetic variations in STXBP5, STX2 and the VWF promoter were not associated with VWF:Ag levels at baseline nor with the
VWF:Ag increase.
Conclusions: VWF:Ag levels strongly increase upon exhaustive exercise and this increase is strongly determined by physical
fitness level and the intensity of the exercise, while there is no clear effect of genetic variation in STXBP5, STX2 and the VWF
promoter.
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Introduction
Blood coagulation changes in response to physical exercise [1–
6]. One of the major players in blood coagulation is von
Willebrand factor (VWF), a multifunctional glycoprotein that
initiates primary haemostasis. Ultralarge very active VWF multi-
mers are cleaved by A Disintegrin and Metalloprotease with ThromboS-
pondin motif repeats 13 (ADAMTS13) into smaller, less prothrombo-
tic forms. It is well known that levels of VWF increase steeply upon
intense physical exercise [7]. To date it is not fully understood
which mediators, both non-genetic and genetic, affect VWF
response to stress. However, it is of great interest to discover new
determinants of the excretion mechanism of VWF molecules, since
high VWF levels have been associated with venous thrombosis [8]
and arterial thrombosis [9–11].
VWF is mainly synthesized by endothelial cells and marks
endothelial cell activation [12,13]. The majority of the freshly
synthesized VWF molecules are constitutively released into the
circulation. A small part of especially large VWF multimers 2
harbouring the greatest haemostatic potential 2 is stored in
Weibel Palade Bodies of endothelial cells [14–17]. Numerous
agonists initiate the release from these storage granules, including
hypoxia, epinephrine, histamine, thrombin, fibrin, and vasopressin
[18,19].
Plasma VWF levels have a wide biological variation, since
numerous lifestyle factors, environmental factors, and genetic
factors continuously influence VWF levels in the circulation [19].
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Previous studies among human twins have demonstrated that
more than half of the variability in VWF levels is caused by genetic
variations in the genome [20,21]. The most important genetic
determinant is ABO blood group [22]. In addition, recently six
new genetic loci have been discovered using a hypothesis-free
approach with genome-wide association studies [23]. Two of the
newly identified genetic loci, Syntaxin Binding Protein-5 (STXBP5)
and Syntaxin-2 (STX2), are of specific interest, since their encoding
proteins interact with SNARE complex proteins, such as SNAP23
and syntaxin-4, which have been shown to be involved in Weibel
Palade Body (WPB) exocytosis, a well-known mechanism for the
secretion of VWF molecules by endothelial cells [24]. Another
genetic modulator is the VWF promoter in which four single
nucleotide polymorphisms (SNPs) have been identified, that are
associated with VWF levels [25,26].
We aimed to identify important mediators, including lifestyle
factors, environmental factors, and common genetic variations in
the STXBP5, STX2 and VWF promoter genes, of VWF response




The study was approved by the medical ethical committee at
Erasmus University Medical Center and written informed consent
was obtained from all participants at inclusion.
Study participants
For the ‘‘RESPOnse’’ (Role of SNARE protein genes in the
regulation of von Willebrand Factor concentration and other
coagulation factors) study, we included 105 healthy individuals,
who were between 18 to 35 years of age and of North-European
ancestry. Exclusion criteria were known cardiovascular risk
factors, including hypertension, hypercholesterolemia, diabetes,
obesity (BMI . 30 kg/m2), and a positive family history of
cardiovascular disease. In addition, participants never had a
thrombotic event or coagulation disorder, were non-smokers, had
no known malignancies, no liver or renal dysfunction, did not use
medication that may influence VWF levels and were not pregnant.
Oral contraceptives use was allowed in this study. Subjects were
requested to abstain from caffeinated and alcoholic beverages
twelve hours prior to the test and to avoid heavy or high-intensity
physical exercise and sports activities on the day of the test.
Baseline measurements
At baseline, all patients received a questionnaire on current
health status and physical condition. We measured weight using a
calibrated digital scale (SECA GmbH & co, model 861) and height
using a wall mounted telescopic height rod (SECA GmbH & co,
model 220). Blood pressure was measured in an upright sitting
position with a calibrated sphygmanometer (Welch Allyn, model
Maxi-Stabil 3) and left upper-arm adjusted cuff size (WelchAllyn,
FlexiPort reusable blood pressure cuff). Also, before the start of the
cycle ergometer test, we performed a rest electrocardiogram
(ECG) to exclude abnormalities in electric conduction through the
heart, arrhythmias etc. All participants declared to be in good
health and none of them had medical contra-indications for
participation in the study.
Cycle ergometer maximal test
Each participant performed an incremental exercise test until
exhaustion, performed on a cycle ergometer (Ergoline, ER800,
Lode, the Netherlands) using a linearly increasing (12 or 18.5 W
min-1) ramp protocol. These slopes were chosen to achieve
exhaustion within 8–12 minutes as recommended by Zhang et al
[27]. Participants started with a warming-up phase of 4 minutes
without resistance. They were instructed to pedal at a frequency
between 60 and 80 rotations per minute (rpm). The loaded phase
was terminated when pedalling frequency dropped below 60 rpm
and was followed by cooling-down for at least 2 minutes.
Cardiac function was monitored using a 12-lead electrocardio-
gram with heart rate (HR) being recorded continuously. Respi-
ratory gas exchange measurements were performed continuously
by using a computerized metabolic cart (Oxycon Pro, Carefusion,
the Netherlands) that was calibrated before each test. Maximal
whole-body oxygen uptake capacity was defined in the present
study as VO2 remaining unchanged or increasing less than 1 ml/
min/kg for 30 sec or more despite an increment in work load [28].
VO2 is the capacity to transport and use oxygen during exercise
and is a measure for physical fitness. The ventilatory threshold
(VT1) was determined by an increase in ventilation (Ve)/VO2 but
without a concomitant increase in Ve/VCO2. The ventilatory
threshold represents the moment at which metabolism changes
from aerobic to anaerobic. Two experienced exercise physiologists
reviewed the plots averaged over 30 sec of the Ve/VO2 and Ve/
VCO2 and determined VT1 values. In case of disagreement, the
opinion of a third investigator was sought. The metabolic
equivalent (METs) score is calculated by the VO2 max and
VO2 VT1 values (1 MET = 3.5 ml/min/kg VO2). A METs
score (calculated by the VO2 max) above 10 represents activities
associated with significant exertion. A METs score calculated by
the VO2 VT1 represents the intensity to sustain activities for 1
hour and is a measurement of the physical fitness of an individual.
The power output (W) was assessed to establish the workload
capacity of the participant. Power output is dependent on physical
fitness, but also on talent. Finally, maximum respiratory exchange
ratio (RER) at peak power output was determined. The RER is a
ratio between the amount of carbon dioxide (CO2) exhaled and
the amount of oxygen (O2) inhaled per breath. Together with the
maximum achieved heart rate as percentage of age-predicted
heart rate (i.e. 208-0.7*age) [29], the maximum RER is a measure
for the intensity of the test.
Blood sampling
Venous blood was drawn from the forearm before and directly
after exhaustion (within 1 minute) via a cannula in the antecubital
vein using a Vacutainer system (Becton-Dickinson, Plymouth,
UK). The first 2 ml of blood was discarded at every time point.
Blood for coagulation measurements was collected in 3.2%
trisodium citrate (9:1 vol/vol). Citrated blood was centrifuged
within 1 hour at 3500 rpm for 10 min at 4uC. Plasma was
additionally centrifuged at 14 000 rpm at room temperature and
stored in aliquots at 280uC. For DNA isolation we stored the
buffy coats of the remaining citrated blood at 220uC until use.
Genomic DNA was isolated according to standard salting-out
procedures and stored at 4uC for genetic analysis.
Laboratory measurements
VWF antigen (VWF:Ag) was determined with an in-house
ELISA with polyclonal rabbit anti-human VWF antibodies and
horseradish peroxidase conjugated anti-human VWF antibodies
(DakoCytomation, Glostrop, Denmark) for catching and tagging,
respectively.
VWF collagen binding (VWF:CB) was determined with an in-
house ELISA using collagen bovine antibodies and horseradish
peroxidase conjugated anti-human VWF antibodies (DakoCyto-
VWF Response to Exhaustive Physical Exercise
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mation, Glostrop, Denmark) for catching and tagging, respective-
ly.
ADAMTS13 activity was measured by a Fluorescence Reso-
nance Energy Transfer Substrate (FRETS) assay using a
fluorescent VWF peptide consisting of 73 amino acids (FRETS-
VWF73). Plates were read with BioTek’s microplate reader
(BioTek). The intra-assay coefficients of variation for VWF:Ag,
VWF:CB and ADAMTS13 were 1.9%, 4.5% and 3.6%,
respectively. The inter-assay coefficients of variation for VWF:Ag,
VWF:CB and ADAMTS13 were 8.3%, 7.9% and 7.5%,
respectively.
Genotyping
The STXBP5 gene spans 182 kbps and is located in the q24
region of chromosome 6. Initially, we obtained data from the
International HapMap project (phase II November 2008 http://
www.hapmap.org) on the linkage disequilibrium (LD) pattern and
selected haplotype-tagging single-nucleotide polymorphisms (ht-
SNPs) using Haploview software (version 3.11; www.broad.mit.
edu/mpg/haploview/index/php). For the STXBP5 and STX2
genes blocks of haplotypes with a frequency of $ 3% were defined
in order to select these ht-SNPs. We took potential functionality
into consideration by preferentially selecting non-synonymous ht-
SNPs or SNPs that are located in known regulatory elements. We
considered only SNPs that were present in a Caucasian
population. Of these ht-SNPs, three were significantly associated
with VWF:Ag levels in our previous study among young patients
with arterial thrombosis and healthy controls [30]. Therefore, we
selected and genotyped only these three SNPs in STXBP5
(rs1039084 and rs9399599) and in STX2 (rs7978987) for our
current study. The polymorphisms in STXBP5, rs1039084 and
rs9399599, are in high linkage disequilibrium with rs9390459,
which had the highest genome wide significance level for VWF
plasma levels in the meta-analysis of the CHARGE consortium
(D’ = 1.00, R2= 0.87 for rs9399599 and D’= 0.96, R2= 0.86 for
rs1039084) (phase II November 2008 http://www.hapmap.org).
Also, rs7978987 in STX2 had a highly significant P value of
3.82610211 in this meta-analysis[23].
The gene encoding VWF is approximately 180 kb in length,
contains 52 exons and is located on chromosome 12. Four SNPs in
this gene have been identified, which are in strong linkage
disequilibrium and segregate as two haplotypes [25,31]. We have
selected and genotyped one of these SNP’s (rs7965413).
Genotyping was done using Custom TaqMan Genotyping
Assays (Applied Biosystems, Foster City, CA, USA). Endpoint
fluorescence was measured on the ABI 7900HT instrument
(Applied Biosystems, Foster City, CA, USA) and clustered
according to genotype using SDS 2.1 software (Applied Biosys-
tems, Foster City, CA, USA). Genotyping was successful for each
SNP in on average 97% of all subjects.
Statistical Analysis
Data on baseline characteristics are presented as means and
standard deviations for continuous variables and as counts and
percentages for categorical data. Since VWF:Ag levels were
skewed, these data were natural logarithmically transformed
(lnVWF:Ag) and presented as median and interquartile range
(IQR). Mann-Whitney tests were used for unpaired two-group
comparisons of non-parametric data.
The association between baseline characteristics and perfor-
mance related determinants with lnVWF:Ag increase were
assessed with linear regression models. Logistic regression was
used to assess the relationship between VWF:Ag response and
baseline characteristics, using VWF:Ag response as categorical
variable. VWF:Ag increase was divided into two categories: low
response with a VWF:Ag increase below the median (,0.40 IU/
mL) and high response with a VWF:Ag increase above the median
($ 0.40 IU/mL). Gender differences in performance-related
determinants were assessed with univariate analysis of variance
(ANOVA). The power output and the VO2 were adjusted for
weight and presented as the value per kg.
Allele frequencies of the VWF polymorphisms were calculated
by genotype counting. For each SNP, the deviation from the
Hardy-Weinberg equilibrium was tested by means of a Chi-
squared test with one degree of freedom. We used linear regression
analyses with additive genetic models to determine the association
between genetic variations in VWF and lnVWF:Ag levels. We had
a power of 0.80 to detect a difference of 0.2 between carriers of the
minor allele and carriers of the common allele, assuming a minor
allele frequency of 0.40. Beta-coefficients represent the increase in
lnVWF:Ag levels per coded allele. Statistical analyses were
performed with SPSS for Windows, version 20.0 (SPSS Inc,
Chicago, USA). A two-sided value of p,0.05 was considered
statistically significant.
Results
In the current study, 105 healthy individuals were included.
Baseline characteristics are shown in table 1. The mean age was 24
years and 61% were female. Blood pressure (mean 114/
70 mmHg) and BMI (mean 23 kg/m2) were within the normal
range. Of all subjects, 86 (82%) used alcoholic beverages. Of all
female participants, 33 women (52%) used oral contraceptives,
seven women (11%) had an intra-uterine device (MirenaH), and
two women (3%) had a Nuva ringH.
The median VWF:Ag level at baseline was 0.94 IU/mL and
increased with 47% after exhaustive exercise to a median
maximum VWF:Ag of 1.38 IU/mL (p,0.0001) (Table 1, Figure
1). The median VWF:CB level at baseline was comparable with
the VWF:Ag level, 0.93 IU/mL, and increased with 43% to a
median maximum of 1.36 IU/mL (p,0.0001). The absolute
increase in VWF:Ag and VWF:CB levels was highly correlated (R
0.81, p,0.0001). The VWF:CB/VWF:Ag ratio was 1.00 at
baseline and was decreasing to 0.96 at maximum exercise.
ADAMTS13 levels also increased after exhaustive exercise with
12% (Table 1, Figure 1). There was no correlation between the
absolute increase in VWF:Ag level and ADAMTS13 (R 0.06,
p = 0.57).
Baseline characteristics were not associated with baseline
VWF:Ag levels (table 2). As expected, blood group non-O was
associated with higher baseline VWF:Ag levels (geometric mean of
VWF:Ag for blood group O: 0.8260.03 IU/mL and for non-O:
1.0860.05 IU/mL). Sex, systolic blood pressure, and diastolic
blood pressure were significantly associated with the VWF:Ag level
response (Table 2 and Figure 2). Alcohol consumption, defined as
any amount of glasses per week, was borderline significantly
associated with a lower VWF:Ag response (p = 0.06). The strongest
determinant was sex. In a multivariate model including sex, blood
pressure, and alcohol consumption, only sex remained significantly
associated with VWF:Ag levels (beta-coefficient for males 0.79
[95% CI 0.52;1.06], p,0.0001).
At baseline, we observed no difference in VWF:Ag levels
between males and females (median [IQR]: females 0.95 IU/mL
[0.78;1.12] and males 0.91 IU/mL [0.74;1.11], p= 0.50). At
exhaustion, males had significantly higher VWF:Ag levels than
females (females 1.22 IU/mL [1.06;1.58] and males 1.66 IU/mL
[1.24;2.05], p= 0.001). OAC use was not associated with the
VWF:Ag level response to exercise.
VWF Response to Exhaustive Physical Exercise
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Next, we investigated the association between performance
related determinants and the VWF:Ag response (table 3A). All
performance-related determinants were significantly associated
with the increase in VWF:Ag levels, but not with the baseline
VWF:Ag levels. The strongest performance related determinants
(p,0.0001) were the peak power output per kg bodyweight, the
ratio between the power output at the ventilatory threshold and
the peak power output in Watt, VO2 peak per kg and the
maximum RER at peak power output. Physical fitness, as
represented by the VO2 VT1/max and power output VT1/
max, was negatively associated with the VWF:Ag increase. In
addition, a multivariate regression was performed. However,
strong multicolinearity was observed between all performance-
related variables. Therefore, we selected variables that showed the
least correlation with each other for the multivariate model. To
this end, we used two models with different combinations of
variables. Nevertheless, multicolinearity could not be excluded
completely, whereby the results of the multivariate regression
analysis should still be interpreted with care. Next, we added sex to
model I and model II, which resulted in the loss of the significant
association between sex and VWF:Ag increase (Model I: b=0.27
[95% CI –0.04;0.58], p = 0.09; model II: b=0.23 [95% CI –
0.84;0.54], p= 0.15). Additionally, when stratifying for sex the
association between performance related determinants and the
increase in VWF:Ag levels remained. In table 3B the performance-
related values are presented for males and females separately.
Physical fitness (VO2 VT1/max and power output VT1/max) was
slightly higher in females than in males. The intensity of the test
and the endurance of the participant, as represented by the VO2
peak, peak power output, and the maximum RER, were higher in
males than in females. There was no difference in test duration
between males and females. When excluding women with oral
contraceptives the results of the study did not change.
Finally, we investigated the association between genetic
variations in STXBP5, STX2 and VWF promoter on VWF:Ag
response to exercise (table 4). There was no significant association
between genetic variations and VWF:Ag levels at baseline, at
exhaustion, nor an association with the absolute VWF:Ag increase.
Also, ABO blood group, the most important genetic determinant
of VWF:Ag levels, was not associated with the VWF:Ag level
response to exercise. There was also no significant difference in the
association between VWF increase and genetic variation between
individuals with blood group O and individuals with blood group
non-O (data not shown).
Discussion
In this study among 105 healthy young subjects, VWF:Ag levels
increased significantly upon incremental exhaustive exercise (mean
METs score (max) .10) with a median increase of 47%. The
VWF:Ag response was highly variable and was strongly dependent
on performance-related and physical fitness-related determinants.
Neither baseline characteristics nor the studied genetic determi-
nants of VWF:Ag levels affected the extent of VWF:Ag response to
physical exercise.
VWF:CB levels increased after exhaustive exercise in the same
proportion as VWF:Ag levels. ADAMTS13 levels at baseline were
in the high normal range. This study included young and healthy
individuals and a previous study also showed higher levels in
young individuals [3]. ADAMTS13 levels increased after exhaus-
tion, although it was to a lower extent than VWF levels. A previous
study showed similar results as ADAMTS13 increased after
exercise in patients with von Willebrand disease type 2B [3].
However, in another study in healthy individuals there was no
difference in ADAMTS13 between baseline and immediately after
Table 1. Baseline characteristics.
N=105
Age (years) 24.364.4
Female sex, N (%) 64 (61%)
Systolic blood pressure (mmHg) 114612
Diastolic blood pressure (mmHg) 7069
Heart rate (bpm) 76610
BMI (kg/m2) 2362
Oral contraceptives (% of total women) 33 (52%)
Blood group O, N (%) 54 (51%)
METs score (max) 12.462.4
METs score (VT1) 8.661.9
VWF:Ag baseline (IU/mL), median (IQR) 0.94 (0.77–1.12)
VWF:Ag maximum (IU/mL), median (IQR) 1.38 (1.10–1.84)
VWF:Ag absolute increase (IU/mL), median (IQR) 0.40 (0.23–0.70)
VWF:Ag relative increase (%), median (IQR) 47 (25–73)
VWF:CB baseline (IU/mL), median (IQR) 0.93 (0.75–1.17)
VWF:CB maximum (IU/mL), median (IQR) 1.36 (1.11–1.68)
VWF:CB absolute increase (IU/mL), median (IQR) 0.37 (0.17–0.67)
VWF:CB relative increase (%), median (IQR) 43 (19–69)
ADAMTS13 baseline (U/ml), median (IQR) 1.28 (1.11–1.42)
ADAMTS13 maximum (U/ml), median (IQR) 1.46 (1.24–1.58)
ADAMTS13 absolute increase (U/ml), median (IQR) 0.15 (0.07–0.24)
ADAMTS13 relative increase (%), median (IQR) 12 (6–19)
VWF:CB/VWF:Ag ratio baseline, median (IQR) 1.00 (0.91–1.10)
VWF:CB/VWF:Ag ratio maximum, median (IQR) 0.96 (0.89–1.05)
Summary statistics for continuous variables are presented as mean 6 standard
deviation. Categorical data are summarized as percentages. VWF:Ag, VWF:CB
and ADAMTS13 levels and the VWF:CB/VWF:Ag ratio are presented as median
and interquartile range (IQR).
doi:10.1371/journal.pone.0091687.t001
Figure 1. Levels (U/ml) of VWF:Ag, VWF:CB, ADAMTS13 and
the ratio VWF:CB/VWF:Ag at baseline and maximum. P values
represents the difference between baseline and maximum levels.
doi:10.1371/journal.pone.0091687.g001
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exercise [3,5]. In addition, ADAMTS13 decreased after infusion
of desmopressin, which induces a release of large VWF multimers
into the circulation, in healthy individuals [32]. However, all these
studies included only low number of patients.
As the average maximal achieved heart rate as a percentage of
age-predicted maximum heart rate was 9766%, together with a
plateauing of oxygen uptake and a mean RER of 1.1560.08, our
test protocol can be considered as an exhaustive cycle ergometer
test in our subjects [33,34].
In our study, VWF:Ag levels increased significantly upon
physical exercise. This was comparable with a previous study
which showed a significant increase in VWF:Ag levels post
exercise and 15 minutes after exercise [35]. We found a higher
increase in VWF:Ag response upon exercise in males compared
with females. After stratifying for sex, the association between the
performance related determinants and the VWF:Ag increase did
not change. This indicates that the role of physical fitness and the
intensity of the test on VWF:Ag response upon exercise is
independent of sex. Women taking oral contraceptives were not
Table 2. Association between baseline characteristics and VWF:Ag levels.
Baseline VWF:Ag levels Absolute VWF:Ag increase
Beta-coefficient [95% CI] P-value Beta-coefficient [95% CI] P-value
Age 0.01 [–0.004; 0.02] 0.18 –0.03 [–0.06;0.01] 0.14
Male sex –0.02 [–0.14;0.10] 0.73 0.79 [0.54;1.04] , 0.0001
Systolic blood pressure 0.001 [–0.01;0.01] 0.93 0.02 [0.003;0.03] 0.02
Diastolic blood pressure –0.004 [–0.11;0.002] 0.21 0.02 [0.001;0.03] 0.04
BMI –0.002 [–0.03;0.02] 0.90 0.02 [–0.05;0.08] 0.60
Alcohol consumption –0.10 [–0.26;0.05] 0.18 –0.36 [–0.74;0.01] 0.06
Blood group non-O 0.28 [0.17;0.39] , 0.0001 –0.10 [–0.39;0.19] 0.48
Oral contraceptives –0.04 [–0.21;0.14] 0.67 –0.23 [–0.59;0.14] 0.22
Univariate linear regression analysis, beta-coefficient represents the increase of lnVWF:Ag levels with 95% confidence interval per unit increase of the selected variable.
doi:10.1371/journal.pone.0091687.t002
Figure 2. Association between baseline characteristics and VWF:Ag response defined by the Odds ratio. VWF:Ag increase divided into
two categories: low response with a VWF:Ag increase below the median (,0.40 IU/ml) and high response with a VWF:Ag increase above the median
($0.40 IU/ml).
doi:10.1371/journal.pone.0091687.g002
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excluded for this study. As oral contraceptives have effects on
coagulation factors [36] this could have influenced our results.
However, no differences were found when excluding those women
and additionally no significant differences were found between
women using oral contraceptives and women without (data not
shown).
In our study, the VWF:Ag levels increase upon exercise was the
highest in individuals with the lowest physical fitness, although this
was not significant after multivariate analysis, and in individuals
with the most intensive exercise. Intensive physical exercise is
associated with more recruitment of capillaries in the muscle and
additionally an increase in vascular conductance in muscle
composed predominantly of fast-twitch oxidative (type IIa) and
fast-twitch glycolytic (type IIb) fibers [37]. This results in more
endothelial exposure to shear stress and adrenergic stimulation,
which may explain the increased release of VWF upon exercise.
The highest VWF:Ag response in individuals with the lowest
physical fitness underlines the hypothesis that frequent physical
Table 3. Performance-related determinants of VWF:Ag increase and mean differences between males and females.
A B
Univariate Multivariate Model I Multivariate Model II Males Females
b [95% CI] b [95% CI] b [95% CI] N=41 N=64 P-value
Peak Power Output per kg 0.57 [0.42;0.72]* 0.51 [0.36;0.65]* 4.460.1 3.460.1 , 0.0001
Watts per kg VT1 0.42 [0.17;0.66]{ 2.860.1 2.360.1 , 0.0001
Watts VT1/ Watts max –2.57 [–3.95; –1.20]* –1.02 [–2.36;0.33] 6361 6761 0.04
VO2 peak per kg 0.05 [0.03;0.06]* 0.04 [0.03;0.06]* 50.261.0 39.260.8 , 0.0001
VO2 VT1 per kg 0.03 [0.01;0.05]{ 33.960.9 27.960.7 , 0.0001
VO2 VT1/VO2 peak –2.14 [–3.55; –0.72]{ –0.41 [–1.66;0.83] 6862 7261 0.051
Max Respiratory Exchange Ratio 3.75 [2.01;5.49]* 2.52 [0.79;4.25]{ 2.49 [0.90;4.07]{ 1.1860.01 1.1360.01 0.001
Test duration 0.09 [0.03–0.15]{ 18.160.3 18.260.3 0.90
Linear regression analysis with natural log VWF:Ag as dependent. Beta-coefficient represents the increase in lnVWF:Ag per unit increase of the selected variable.*
p,0.0001, { p,0.01.
A Performance related determinants of VWF:Ag increase in the total population.
B Gender differences in performance-related determinants.
doi:10.1371/journal.pone.0091687.t003
Table 4. VWF:Ag levels per genotype of polymorphisms in STXBP5, STX2 and VWF promoter.
N Baseline (IU/mL) Exhaustion (IU/mL) Absolute difference (IU/mL)
rs1039084 (STXBP5)
GG 33 0.9460.06 1.4560.08 0.5260.06
AG 44 1.0260.05 1.5660.07 0.5460.05
AA 25 0.9660.06 1.4260.10 0.4660.06
P for trend 0.44 0.44 0.67
rs9399599 (STXBP5)
AA 32 0.8960.06 1.4060.09 0.5160.06
AT 45 1.0560.05 1.5960.07 0.5460.05
TT 25 0.9660.06 1.4160.10 0.456 0.06
P for trend 0.11 0.18 0.56
rs7978987 (STX2)
GG 48 0.9860.05 1.4360.07 0.4560.05
AG 45 0.9860.05 1.5560.07 0.5760.05
AA 12 0.9460.09 1.4260.14 0.4760.09
P for trend 0.94 0.43 0.18
rs7965413 (VWF
promoter)
AA 47 1.0160.05 1.4860.07 0.4760.05
AG 40 0.9460.05 1.4360.08 0.4960.05
GG 13 1.0360.09 1.6160.13 0.5860.09
P for trend 0.55 0.50 0.55
doi:10.1371/journal.pone.0091687.t004
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exercise has a positive effect on cardiovascular risk. This is in
contrast with a previous study which showed no difference in
VWF:Ag increase upon exercise between resistance trained and
untrained individuals [35]. However, in this study only a small
number of individuals were included (N= 20). For a long time it
has been anticipated that regular physical exercise has a
favourable effect on many biological mechanisms, thereby
improving health and fitness. Regular physical exercise is
associated with a decreased all-cause mortality and with a reduced
cardiovascular risk [38]. The positive effects of physical exercise on
cardiovascular disease development may be induced by alterations
in haemostasis that lead to a hypocoagulable state. This
hypocoagulable state is achieved by a compensatory exhaustion
of platelets in physically active individuals and underlines the
beneficial effects of exercise on long-term prevention of cardio-
vascular disease [39]. In our study, the baseline VWF:Ag levels
were not associated with physical fitness or intensity of the test.
This observation is in line with previous findings that showed that
levels of coagulation factor VII (FVII), VWF, and FVIII at rest
were similar in professional athletes and controls [40]. There are
multiple factors which could have influenced our results, including
the type of sport and the training status of the participants, which
are known to influence e.g. capillary density and in vivo
endothelial function in skeletal muscle. However, the majority of
our subjects participated in recreational type of sports activities
and can be regarded as a representative sample of healthy active
individuals.
STXBP5 and STX2 are two novel genetic loci that have been
associated with VWF:Ag levels in the general population [23]. In
addition, genetic variation within these genes affects VWF:Ag
levels in young patients with a first event of arterial thrombosis
[30]. Considering the involvement of the STXBP5 and STX2
encoding proteins in the regulated secretion of VWF molecules,
our hypothesis was that genetic variants within these genes would
affect the release of VWF molecules, but not the steady state levels,
which are determined by the constitutive pathway. To this end, we
included young individuals below the age of 35 years to exclude
the presence of extensive atherosclerosis, which is related to
endothelial dysfunction and consequent higher VWF:Ag levels.
Their baseline VWF:Ag levels therefore represent a steady state
situation. To provoke release of VWF molecules from Weibel
Palade Bodies in our study, all participants performed exhaustive
physical exercise, which induces beta-adrenergic receptor activa-
tion [41] and subsequent endothelial cell activation. Genetic
variation in STXBP5 and STX2 was not associated with VWF:Ag
levels at baseline, though we had sufficient power to detect the
previously observed effect of these genetic variants. The VWF:Ag
increase upon exercise was also not affected by genetic variation in
STXBP5 and STX2. This finding was in contrast to our hypothesis.
In addition, we genotyped a common variation in the VWF
promoter gene. Previous studies have shown an association
between this genetic variation and VWF:Ag levels at baseline
[25,31]. However, other studies have failed to show an effect of
this polymorphism on VWF levels under normal conditions [42–
44]. Despite the fact that the influence of genetic variation in the
VWF promoter on VWF levels has never been studied in arterial
thrombosis or at stress before, we hypothesized that a genetic
variation in this gene would affect the expression of VWF at
physical exercise resulting in a difference in VWF plasma levels. In
our study, we could not find a significant association between
baseline VWF:Ag levels and genetic variations in the VWF
promoter gene, probably caused by a relatively small study
population. Furthermore, the VWF:Ag increase upon exercise was
also not associated with the VWF promoter. This suggests that, in
contrast to our hypothesis, the VWF release is not depending on
genetic variations in the VWF promoter at exhaustive physical
exercise.
The negative results of the influence of genetic variation on
VWF increase may be caused by the fact that genetic variations in
STXBP5 and STX2 may not be involved in WPB exocytosis. In
addition, VWF is also stored in alpha-granules of platelets and the
contribution of platelet VWF to plasma levels upon exercise is not
known [45]. Therefore, VWF release from platelet alpha-granules
during exercise cannot be excluded and might explain the negative
results of the role of genetic variations involved in Weibel Palade
Body exocytosis. Furthermore, we observed that the VWF:Ag
increase was highly variable and strongly dependent on physical
fitness and the intensity of the exercise performed. Consequently,
the effect of environmental factors may have been stronger than
the genetic effect.
Another important genetic determinant of VWF:Ag levels is
blood group [46]. Individuals with blood group O have 25% lower
VWF:Ag levels than individuals with blood group non-O, because
the presence of blood group A and B antigens on VWF molecules
leads to a decreased clearance of VWF molecules [47]. Further-
more, blood group non-O has been associated with an increased
risk of CHD [48–50]. Ribeiro et al. observed that males with blood
group non-O (N=8) had higher post-exercise VWF:Ag levels than
males with blood group O (N=8), although the rise of VWF:Ag
was not statistically significantly different between the groups [51].
In our study, subjects with blood group non-O had higher levels at
exhaustion (median [IQR], 1.60 IU/mL [1.2–2.0]), than subjects
with blood group O (1.29 IU/mL [1.1–1.6], p = 0.03). However,
blood group was not associated with the VWF:Ag increase upon
exercise (0.49 IU/mL [0.2–0.8] in non-O versus 0.46 [0.2–0.7] in
O, p= 0.34). Assuming that exercise induces the release of VWF
molecules from its storage granules and the clearance does not
change during exercise, it was expected that subjects with blood
group O and subjects with blood group non-O had a similar
increase after exercise. In this study, we only included young
healthy individuals and therefore the results of the study cannot be
extrapolated to the older population. However, those individuals
were included to exclude the presence of extensive atherosclerosis
which represents a steady state situation.
In conclusion, we have shown in a large and homogeneous
group of young healthy individuals that VWF:Ag levels increase
strongly upon exhaustive physical exercise and is primarily
dependent on physical fitness and the intensity of the exercise
performed. Genetic variations in STXBP5, STX2 and VWF
promoter that have previously been identified as important genetic
determinants of VWF:Ag levels, were not associated with the
VWF:Ag response to physical exercise. Also, ABO blood group,
the most important genetic determinant of VWF:Ag levels was not
associated with the VWF:Ag increase. These findings suggest that
environmental factors may be more important than genetic factors
in determining the VWF:Ag response to stress.
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